New pharmaceuticals: public research combines efficiency with contained costs

Credit: CC0 Public Domain

Is the basic research that goes into the development of new drugs more efficiently conducted by public-sector scientists, pharmaceutical firms, or independent private laboratories? What role do each of these groups play in determining prices of innovative pharmaceuticals, which have risen steeply over the last years?

To answer these questions, economists Francesca Barigozzi, of the University of Bologna, and Izabela Jelovac, of the CNRS, designed and studied a model inspired by .

In an article recently published in Health Economics, they demonstrate that basic research is most cost-effective when carried out either in a public research laboratory or a pharmaceutical firm. If basic and applied research are highly complementary—where improving the quality of one benefits the other—public research units outperform in the conduct of basic research.

Furthermore, the price of new drugs is lowest when basic research takes place in public labs. These findings therefore condition the validity of the economic assumption that greater efficiency in research necessarily results in a more expensive end product. In some cases, public-sector basic research is the most efficient and leads to the lowest drug prices.

Explore further

Is it time to nationalize the drug industry?

More information: Francesca Barigozzi et al, Research funding and price negotiation for new drugs, Health Economics (2020). DOI: 10.1002/hec.4113
Journal information: Health Economics

Provided by CNRS
Citation: New pharmaceuticals: public research combines efficiency with contained costs (2020, June 29) retrieved 10 July 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments